A post hoc analysis evaluates zanubrutinib vs acalabrutinib-venetoclax in treatment naive chronic lymphocytic leukemia using indirect comparisons of data from two phase 3 trials.

Tanya Siddiqi, MD, highlights long-term safety outcomes with first-line zanubrutinib (Brukinsa) in patients with chronic ...

Acalabrutinib and venetoclax, with or without obinutuzumab, improved PFS over chemoimmunotherapy in newly diagnosed CLL patients. The fixed-duration regimen offers potential cost savings and reduced ...

Tanya Siddiqi, MD, shares her personal experience using continuous BTK inhibitor therapy for the treatment of patients with ...

Researchers sought to determine whether fixed-duration treatment with venetoclax + obinutuzumab/ibrutinib would have similar efficacy to continuous ibrutinib therapy in CLL.

The FDA has approved a fixed-duration, all-oral regimen of acalabrutinib plus venetoclax for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The decision, ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has positive data suggesting two fixed-duration combinations containing its ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and ...